Margery Cunningham - Extendicare Independent Director
| EXETFDelisted Stock | USD 5.00 0.00 0.00% |
Director
Ms. Margery O. Cunningham is Independent Director of Extendicare Inc. Ms. Cunningham was a Vice President at Avalere Health, a leading advisory firm focused on health care business strategy and public policy since August 2011. Prior thereto, Ms. Cunningham was with Lehman Brothers from 1997 to 2008, during which time she held a number of progressively senior executive roles, including as Managing Director and Global Head of Product Training, Associate Director of Credit Research, and High Yield Bond Analyst. Her research career spanned more than 20 years, including both equity and fixed income research for firms such as Kidder, Peabody Co., and Paine Webber. As an analyst, Ms. Cunningham was a perennial Institutional Investor magazine allstar analyst in the high yield health care category. In addition, from 1995 to 1997, Ms. Cunningham served as the Director, Financial Planning and Analysis for Marriott Management Services, performing strategic and financial analysis on acquisitions since 2010.
| Age | 58 |
| Tenure | 14 years |
| Professional Marks | CFA |
| Phone | 905 470 4000 |
| Web | https://www.extendicare.com |
Extendicare Management Efficiency
The company has return on total asset (ROA) of 0.1102 % which means that it generated a profit of $0.1102 on every $100 spent on assets. This is way below average. Extendicare's management efficiency ratios could be used to measure how well Extendicare manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 463.27 M in total debt with debt to equity ratio (D/E) of 2.85, implying the company greatly relies on financing operations through barrowing. Extendicare has a current ratio of 1.07, suggesting that it is not liquid enough and may have problems paying out its financial obligations in time and when they become due. Debt can assist Extendicare until it has trouble settling it off, either with new capital or with free cash flow. So, Extendicare's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Extendicare sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Extendicare to invest in growth at high rates of return. When we think about Extendicare's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Bruce Perkins | Amedisys | 64 | |
| Nathaniel Zilkha | Amedisys | 41 | |
| John Deane | Surgery Partners | 56 | |
| David Bellaire | Medical Facilities | 61 | |
| Christopher Gordon | Surgery Partners | 44 | |
| Joseph Trunfio | Cross Country Healthcare | 70 | |
| Michael Earley | Addus HomeCare | 62 | |
| Michael OKeefe | Nova Leap Health | 46 | |
| Adam Feinstein | Surgery Partners | 45 | |
| Susan Weaver | Addus HomeCare | 57 | |
| John Perri | Medical Facilities | 55 | |
| Mark Perlberg | Cross Country Healthcare | 61 | |
| Linda Hall | Amedisys | 68 | |
| Stephen Dineley | Medical Facilities | 64 | |
| Hartley Rogers | Acadia Healthcare | 56 | |
| EPerot Bissell | Acadia Healthcare | 58 | |
| Mark First | Addus HomeCare | 53 | |
| Patricia Akopiantz | Ramsay Health Care | 50 | |
| Christopher Gordon | Acadia Healthcare | 44 | |
| Matthew Lozow | Surgery Partners | 37 | |
| Kerry Roxburgh | Ramsay Health Care | 71 | |
Management Performance
| Return On Equity | 0.0018 | ||||
| Return On Asset | 0.11 |
Extendicare Leadership Team
Elected by the shareholders, the Extendicare's board of directors comprises two types of representatives: Extendicare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Extendicare. The board's role is to monitor Extendicare's management team and ensure that shareholders' interests are well served. Extendicare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Extendicare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ali Mir, ParaMed VP | ||
| Paul Tuttle, President of Extendicare (Canada) Inc | ||
| Samir Manji, Independent Director | ||
| Timothy Lukenda, CEO and President Non-Independent Director, Chairman of Extendicare (Canada) Inc, Chairman of Extendicare Health Services Inc, CEO of Extendicare (Canada) Inc and CEO of Extendicare Health Services Inc | ||
| Frederic Waks, Vice Chairman of the Board | ||
| Gary Loder, Vice President - Extendicare Assist and SGP Purchasing Partner Network (SGP) of ECI | ||
| MBA MD, Pres CEO | ||
| Jillian Fountain, Corporate Secretary | ||
| John Angus, Independent Director | ||
| Bruce Wienberg, VP Care | ||
| Elaine Everson, CFO and VP | ||
| Margery Cunningham, Independent Director | ||
| Sandra Hanington, Director | ||
| Lisa Pearson, VP Affairs | ||
| Alan Hibben, Director | ||
| David Bacon, CFO, Senior Vice President | ||
| Matthew Morgan, Chief Officer | ||
| Leslie Sarauer, VP Officer | ||
| Donna Kingelin, Director | ||
| Deborah Bakti, VP of HR and Silver Group Purchasing | ||
| Gail Paech, Director | ||
| Michael Harris, Vice President LTC Operations of ECI | ||
| Howard Dean, Independent Director | ||
| Benjamin Hutzel, Independent Chairman of the Board | ||
| Alan Torrie, Director | ||
| Michael Guerriere, Director | ||
| BRANDON PARENT, Vice President General Counsel | ||
| Norma Beauchamp, Independent Director | ||
| John Toffoletto, Chief VP | ||
| Steve Paraskevopoulos, VP CTO | ||
| Aladin Mawani, Director |
Extendicare Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Extendicare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0018 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 556.43 M | ||||
| Shares Outstanding | 83.94 M | ||||
| Shares Owned By Insiders | 13.15 % | ||||
| Shares Owned By Institutions | 17.61 % | ||||
| Price To Earning | 500.00 X | ||||
| Price To Book | 4.28 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Extendicare in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Extendicare's short interest history, or implied volatility extrapolated from Extendicare options trading.
Pair Trading with Extendicare
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Extendicare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Extendicare will appreciate offsetting losses from the drop in the long position's value.Moving against Extendicare Pink Sheet
| 0.59 | NLY-PG | Annaly Capital Management | PairCorr |
| 0.59 | ABR-PE | Arbor Realty Trust | PairCorr |
| 0.57 | NREF-PA | NexPoint Real Estate | PairCorr |
| 0.48 | NLY-PF | Annaly Capital Management | PairCorr |
| 0.46 | MITT-PB | AG Mortgage Investment | PairCorr |
The ability to find closely correlated positions to Extendicare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Extendicare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Extendicare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Extendicare to buy it.
The correlation of Extendicare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Extendicare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Extendicare moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Extendicare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Extendicare Pink Sheet
If you are still planning to invest in Extendicare check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Extendicare's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |